Anavex Life Sciences (NASDAQ: AVXL) and Tetralogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Anavex Life Sciences and Tetralogic Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 2 0 3.00
Tetralogic Pharmaceuticals 0 0 0 0 N/A

Anavex Life Sciences presently has a consensus price target of $14.50, indicating a potential upside of 360.32%. Given Anavex Life Sciences’ higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Tetralogic Pharmaceuticals.

Profitability

This table compares Anavex Life Sciences and Tetralogic Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -70.10% -63.39%
Tetralogic Pharmaceuticals N/A N/A N/A

Volatility & Risk

Anavex Life Sciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500.

Insider & Institutional Ownership

23.9% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 0.0% of Tetralogic Pharmaceuticals shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 15.4% of Tetralogic Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Anavex Life Sciences and Tetralogic Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$14.73 million ($0.33) -9.55
Tetralogic Pharmaceuticals N/A N/A -$49.72 million ($1.65) -0.02

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Anavex Life Sciences beats Tetralogic Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Tetralogic Pharmaceuticals Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.